Loading
A phase 3 trial of Osimertinib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) is a phase 3 interventional study registered as NCT05629234 by AstraZeneca, with 37 participants enrolled, started 2023-05-08 and due to reach its primary completion in 2027-02-22. Interventions recorded: Osimertinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Parexel, AstraZeneca and the tag pipeline.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Parexel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Parexel, AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/